Literature DB >> 19752745

No correlation between clinical response to CTLA-4 blockade and presence of NY-ESO-1 antibody in patients with metastatic melanoma.

Stephanie L Goff, Paul F Robbins, Mona El-Gamil, Steven A Rosenberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19752745      PMCID： PMC6327840          DOI： 10.1097/CJI.0b013e3181affbf0

Source DB:  PubMed          Journal:  J Immunother        ISSN： 1524-9557            Impact factor:   4.456


× No keyword cloud information.
  7 in total

1.  Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

Authors:  Peter Attia; Giao Q Phan; Ajay V Maker; Michael R Robinson; Martha M Quezado; James C Yang; Richard M Sherry; Suzanne L Topalian; Udai S Kammula; Richard E Royal; Nicholas P Restifo; Leah R Haworth; Catherine Levy; Sharon A Mavroukakis; Geoff Nichol; Michael J Yellin; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

2.  Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

Authors:  Kimberly E Beck; Joseph A Blansfield; Khoi Q Tran; Andrew L Feldman; Marybeth S Hughes; Richard E Royal; Udai S Kammula; Suzanne L Topalian; Richard M Sherry; David Kleiner; Martha Quezado; Israel Lowy; Michael Yellin; Steven A Rosenberg; James C Yang
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

3.  Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.

Authors:  Joseph A Blansfield; Kimberly E Beck; Khoi Tran; James C Yang; Marybeth S Hughes; Udai S Kammula; Richard E Royal; Suzanne L Topalian; Leah R Haworth; Catherine Levy; Steven A Rosenberg; Richard M Sherry
Journal:  J Immunother       Date:  2005 Nov-Dec       Impact factor: 4.456

4.  CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.

Authors:  Jianda Yuan; Sacha Gnjatic; Hao Li; Sarah Powel; Humilidad F Gallardo; Erika Ritter; Geoffrey Y Ku; Achim A Jungbluth; Neil H Segal; Teresa S Rasalan; Gregor Manukian; Yinyan Xu; Ruth-Ann Roman; Stephanie L Terzulli; Melanie Heywood; Evelina Pogoriler; Gerd Ritter; Lloyd J Old; James P Allison; Jedd D Wolchok
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-12       Impact factor: 11.205

5.  Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.

Authors:  Stephanie G Downey; Jacob A Klapper; Franz O Smith; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Tamika E Allen; Catherine L Levy; Michael Yellin; Geoffrey Nichol; Donald E White; Seth M Steinberg; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2007-11-02       Impact factor: 12.531

6.  Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.

Authors:  James C Yang; Marybeth Hughes; Udai Kammula; Richard Royal; Richard M Sherry; Suzanne L Topalian; Kimberly B Suri; Catherine Levy; Tamika Allen; Sharon Mavroukakis; Israel Lowy; Donald E White; Steven A Rosenberg
Journal:  J Immunother       Date:  2007 Nov-Dec       Impact factor: 4.456

7.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.

Authors:  Giao Q Phan; James C Yang; Richard M Sherry; Patrick Hwu; Suzanne L Topalian; Douglas J Schwartzentruber; Nicholas P Restifo; Leah R Haworth; Claudia A Seipp; Linda J Freezer; Kathleen E Morton; Sharon A Mavroukakis; Paul H Duray; Seth M Steinberg; James P Allison; Thomas A Davis; Steven A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-25       Impact factor: 12.779
  7 in total
  12 in total

1.  Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.

Authors:  Jianda Yuan; Matthew Adamow; Brian A Ginsberg; Teresa S Rasalan; Erika Ritter; Humilidad F Gallardo; Yinyan Xu; Evelina Pogoriler; Stephanie L Terzulli; Deborah Kuk; Katherine S Panageas; Gerd Ritter; Mario Sznol; Ruth Halaban; Achim A Jungbluth; James P Allison; Lloyd J Old; Jedd D Wolchok; Sacha Gnjatic
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-20       Impact factor: 11.205

2.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

Authors:  Paul F Robbins; Richard A Morgan; Steven A Feldman; James C Yang; Richard M Sherry; Mark E Dudley; John R Wunderlich; Azam V Nahvi; Lee J Helman; Crystal L Mackall; Udai S Kammula; Marybeth S Hughes; Nicholas P Restifo; Mark Raffeld; Chyi-Chia Richard Lee; Catherine L Levy; Yong F Li; Mona El-Gamil; Susan L Schwarz; Carolyn Laurencot; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

Review 3.  Unmasking the immune recognition of prostate cancer with CTLA4 blockade.

Authors:  Serena S Kwek; Edward Cha; Lawrence Fong
Journal:  Nat Rev Cancer       Date:  2012-03-01       Impact factor: 60.716

Review 4.  Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition.

Authors:  Claire F Friedman; Michael A Postow
Journal:  Curr Oncol Rep       Date:  2016-04       Impact factor: 5.075

Review 5.  B cells and antibody production in melanoma.

Authors:  Jessica Da Gama Duarte; Janique M Peyper; Jonathan M Blackburn
Journal:  Mamm Genome       Date:  2018-09-03       Impact factor: 2.957

Review 6.  At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.

Authors:  Margaret K Callahan; Jedd D Wolchok
Journal:  J Leukoc Biol       Date:  2013-05-10       Impact factor: 4.962

Review 7.  Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1.

Authors:  Yi-Chi M Kong; Jeffrey C Flynn
Journal:  Front Immunol       Date:  2014-05-16       Impact factor: 7.561

Review 8.  Novel technologies and emerging biomarkers for personalized cancer immunotherapy.

Authors:  Jianda Yuan; Priti S Hegde; Raphael Clynes; Periklis G Foukas; Alexandre Harari; Thomas O Kleen; Pia Kvistborg; Cristina Maccalli; Holden T Maecker; David B Page; Harlan Robins; Wenru Song; Edward C Stack; Ena Wang; Theresa L Whiteside; Yingdong Zhao; Heinz Zwierzina; Lisa H Butterfield; Bernard A Fox
Journal:  J Immunother Cancer       Date:  2016-01-19       Impact factor: 13.751

9.  Drug targets and predictive biomarkers in the management of metastatic melanoma.

Authors:  Jaykumar Thumar; Eva Giesen; Harriet M Kluger
Journal:  Pharmgenomics Pers Med       Date:  2012-09-28

Review 10.  NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.

Authors:  Remy Thomas; Ghaneya Al-Khadairi; Jessica Roelands; Wouter Hendrickx; Said Dermime; Davide Bedognetti; Julie Decock
Journal:  Front Immunol       Date:  2018-05-01       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.